全球慢性難治性痛風市場：按地區和國家分析和預測（2025-2035 年）

推動慢性難治性痛風市場的主要成長要素之一是痛風及其相關風險因素的盛行率不斷上升。

隨著世界人口老化以及肥胖、高血壓、METABOLIC INC.症候群等文明病的增加，包括慢性和難治性痛風在內的痛風發病率也在上升。患者數量的不斷成長對更有效的治療方法提出了更高的需求。此外，在現有降尿酸藥物無效的難治性病例中，治療選擇有限，從而導致了生物製藥和其他新治療方法的開發。因此，患者對症狀管理和預防長期關節損傷的需求正在推動市場成長。

另一方面，慢性難治性痛風市場的成長面臨一些挑戰，阻礙了其充分發揮潛力。主要挑戰之一是使用聚乙二醇培格洛酶 (Krystexxa) 等生物製藥治療的成本高。對於患有嚴重且難治性痛風的患者來說，此類治療方法至關重要，但費用昂貴，許多患者難以承受，尤其是低收入地區和保險有限的患者。另一個挑戰是患者堅持長期治療計畫。許多痛風藥物，尤其是生物製藥，都是透過注射給藥的，這可能會因副作用、給藥複雜或缺乏病患教育而導致難以繼續治療。

此外，患者和醫療保健提供者對痛風管理缺乏認知和教育，導致誤診和延誤治療，進一步使難治性痛風的管理複雜化。此外，痛風常伴隨的腎臟疾病等併發症使治療計畫變得複雜，並對有效治療該疾病構成障礙。應對這些挑戰對於改善患者治療效果和更廣泛地獲得新治療方法至關重要。

全球慢性難治性痛風市場正經歷幾個重要的新興趨勢。尤其值得注意的是人們對生物製藥的興趣日益濃厚。聚乙二醇重組尿酸酶（Krystexxa）等生物製藥因其針對性的作用機制以及在治療對常規治療無反應的嚴重痛風病例方面具有很高的治療潛力而受到關注。這些治療方法包括單株抗體和酵素抑制劑，在顯著降低尿酸水平、改善痛風石、防止關節損傷等方面表現出了顯著的療效，正在成為治療慢性難治性痛風的核心。隨著對更有效治療的需求不斷增加，生物製藥有望引領市場，刺激下一代生物製藥的進一步創新和研發。

本報告調查了全球慢性難治性痛風市場，並總結了主要趨勢、市場影響因素分析、法律制度、臨床試驗趨勢、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局和主要企業的概況。

目錄

執行摘要

第1章市場：產業展望

• 市場趨勢
• 法律規範
• 流行病學分析
• 臨床試驗分析
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場挑戰
  • 市場機會

第2章 全球慢性難治性痛風市場（按地區）

• 北美洲
• 歐洲
• 亞太地區
  • 主要發現
  • 市場動態
  • 市場規模及預測

第3章 全球慢性難治性痛風市場：競爭格局與公司概況

• 關鍵策略和發展
  • M&A
  • 協同效應活動
  • 業務擴展和資金籌措
  • 產品發布和核准
  • 其他活動
• 公司簡介
  • Amgen Inc.
  • Cartesian Therapeutics, Inc.
  • Arthrosi Therapeutics, Inc.
  • Shanton Pharma Holdings Limited

第4章調查方法

Global Chronic Refractory Gout Market, Analysis and Forecast: 2025-2035

Chronic refractory gout (CRG) is a severe form of gout, a type of arthritis caused by the accumulation of uric acid crystals in the joints. Unlike typical gout, where symptoms respond to standard treatments like NSAIDs or uric acid-lowering drugs, chronic refractory gout is characterized by persistent symptoms that do not improve with conventional therapies. This form of gout often leads to ongoing inflammation, intense pain, and the development of tophi-large deposits of uric acid crystals that form under the skin and around joints.

The condition is challenging to manage, particularly when factors such as non-compliance, inadequate drug response, or co-existing conditions like kidney disease or obesity contribute to its persistence. Treatments for chronic refractory gout include biologic therapies such as pegloticase (Krystexxa), which helps lower uric acid levels in the blood, and other emerging drugs aimed at reducing flare-ups and improving quality of life. While the condition can cause significant joint damage if left untreated, the advent of new treatments offers hope for better management and symptom control in affected individuals.

One of the key drivers of the chronic refractory gout market is the rising prevalence of gout and associated risk factors. As the global population ages and lifestyle-related conditions such as obesity, hypertension, and metabolic syndrome become more prevalent, the incidence of gout, including its chronic and refractory forms, has been increasing. This growing patient population creates a significant demand for more effective treatments. Additionally, the limitations of existing therapies in managing refractory cases, which do not respond to traditional uric acid-lowering medications, have spurred the development of advanced biologics and other novel therapeutic options. This, in turn, drives market growth as patients seek better management options to control symptoms and prevent long-term joint damage.

Despite the growth of the chronic refractory gout market, several challenges persist that can hinder its full potential. One major challenge is the high cost of biologic therapies like pegloticase (Krystexxa), which are essential for treating severe, refractory cases of gout. These treatments can be prohibitively expensive, limiting access for many patients, especially in lower-income regions or for those without comprehensive insurance coverage. Another challenge is patient adherence to long-term treatment regimens. Many gout medications, particularly biologics, are administered via injections, which may lead to non-compliance due to side effects, administration complexity, or a lack of patient education.

Additionally, the lack of awareness and education about gout management among both patients and healthcare providers can contribute to misdiagnosis or delayed treatment, further complicating the management of refractory gout. Furthermore, co-morbid conditions such as kidney disease, which often accompany gout, complicate treatment plans and create additional barriers to achieving effective control of the disease. Addressing these challenges is essential for improving patient outcomes and ensuring broader access to emerging therapies in the chronic refractory gout market.

The global chronic refractory gout market is highly competitive, with several major companies actively involved, including Amgen Inc., Cartesian Therapeutics Inc., Arthrosi Therapeutics Inc., and Shanton Pharma Holdings Limited. These companies are at the forefront of developing and commercializing therapies aimed at addressing the unmet needs in managing chronic refractory gout, with a focus on innovative biologics, novel drug formulations, and targeted treatments to improve patient outcomes in this challenging condition.

The global chronic refractory gout market is experiencing several key emerging trends. One significant trend is the increased focus on biologic therapies. Biologics like pegloticase (Krystexxa) are gaining traction due to their targeted mechanism of action and ability to effectively treat severe, treatment-resistant cases of gout. These therapies, which include monoclonal antibodies and enzyme inhibitors, are becoming the cornerstone of chronic refractory gout treatment, offering substantial improvements in reducing uric acid levels, alleviating tophi, and preventing joint damage. As the demand for more effective treatments grows, biologics are expected to dominate the market, driving further innovation and research into next-generation biologic therapies.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Markets: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiology Analysis
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Chronic Refractory Gout Market (Region), ($Million), 2023-2035

• 2.1 North America
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 North America Chronic Refractory Gout Market, by Country
      • 2.1.3.1.1 U.S.
      • 2.1.3.1.2 Canada
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
  • 2.2.3 Market Sizing and Forecast
    • 2.2.3.1 Europe Chronic Refractory Gout Market, by Country
      • 2.2.3.1.1 Germany
      • 2.2.3.1.2 U.K.
      • 2.2.3.1.3 France
      • 2.2.3.1.4 Italy
• 2.3 Asia Pacific
  • 2.3.1 Key Findings
  • 2.3.2 Market Dynamics
  • 2.3.3 Market Sizing and Forecast
    • 2.3.3.1 Asia Pacific Chronic Refractory Gout Market, by Country
      • 2.3.3.1.1 Japan

3. Global Chronic Refractory Gout Market: Competitive Landscape and Company Profiles

• 3.1 Key Strategies and Development
  • 3.1.1 Mergers and Acquisitions
  • 3.1.2 Synergistic Activities
  • 3.1.3 Business Expansions and Funding
  • 3.1.4 Product Launches and Approvals
  • 3.1.5 Other Activities
• 3.2 Company Profiles
  • 3.2.1 Amgen Inc.
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers/End-Users
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 Cartesian Therapeutics, Inc.
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers/End-Users
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 Arthrosi Therapeutics, Inc.
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Top Competitors
    • 3.2.3.4 Target Customers/End-Users
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View
  • 3.2.4 Shanton Pharma Holdings Limited
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products / Product Portfolio
    • 3.2.4.3 Top Competitors
    • 3.2.4.4 Target Customers/End-Users
    • 3.2.4.5 Key Personnel
    • 3.2.4.6 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Chronic Refractory Gout Market (by Region), $Million, 2024 and 2035
• Figure: Global Chronic Refractory Gout Market Clinical Trial Analysis
• Figure: Global Chronic Refractory Gout Market Key Trends, Analysis

List of Tables

• Table: Global Chronic Refractory Gout Market, Epidemiology Analysis,
• Table: Global Chronic Refractory Gout Market Dynamics, Impact Analysis
• Table: Global Chronic Refractory Gout Market (by Region), $Million, 2024-2035